ESPERITE’s strengthens its diagnostic tests to top the market with eKaryotype, electronic whole-genome Karyotype test for liquid biopsy.
Esperite welcomes Xitong li, Ph.D., ex-Verinata Illumina Director of Bioinformatics.
Geneva, Switzerland – 19 March 2015
Acquisition of distributor
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading adult stem cell storage bank, has acquired its Bulgarian distributor, Tissue Bank Cryo Center Bulgaria AD (‘TBCCB’) for an initial consideration of €1.5 million payable in cash and 100,000 Cryo-Save Group N.V. shares, and a deferred performance payment, payable annually on the achievement of certain goals until 2013. The total acquisition price reflects approximately five times EBIT of TBCCB. The Group expects the acquisition to be earnings enhancing with immediate effect.
Overname van distributeur
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, of ‘de Groep’), de grootste stamcelbank van Europa, heeft zijn Bulgaarse distributeur, Tissue Bank Cryo Center Bulgaria AD (‘TBCCB’), geacquireerd. De overnameprijs bedraagt €1,5 miljoen in contanten en 100.000 aandelen Cryo-Save Group N.V. Daarnaast is gedurende drie jaar een resultaatafhankelijke betaling verschuldigd. De totale acquisitieprijs weerspiegelt ongeveer vijf maal de EBIT van TBCCB. Cryo-Save verwacht dat de acquisitie met onmiddellijke ingang bijdraagt aan de winst per aandeel.
Completion of Acquisition of Italian service company
Further to the announcement made on 27 May 2009, Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s leading stem cell bank, is pleased to announce the completion of the acquistion of Salus Futura Ltd, which holds all shares of Salus Futura Srl, Italy (“Salus Futura”), following the signing of the sale and purchase agreement and transfer of the initial consideration of €0.4 million in return for Salus Futura shares on 10 July 2009.
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s leading stem cell bank, announces that it has agreed to acquire Salus Futura Ltd, United Kingdom, which holds all shares of Salus Futura Srl, Italy (“Salus Futura”), for an initial consideration of €0.4 million payable in cash and a deferred performance related payment, payable annually on the achievement of certain goals until 31 May 2012. The total consideration under the agreement has been capped to avoid the need for shareholder approval. Cryo-Save expects the acquisition to be earnings enhancing on completion.
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save”, or “the Group”), Europe’s leading adult stem cell storage bank, has acquired Cryo-Save Balcanica S.A. (“Cryo-Save Balcanica”) of Athens, for an initial consideration of €4.1 million payable in cash. The acquisition of the Group’s leading distributor in the Balkans, provides Cryo-Save with a platform for further strong growth and increased profitability, and is expected to be earnings enhancing with immediate effect.
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s leading adult stem cell storage bank, has acquired its Spanish distributor, Crio Cord, S.L. (“Crio Cord”) for an initial consideration of €16 million payable in cash and a deferred performance payment, payable annually on the achievement of certain goals until 2011. Cryo-Save expects the acquisition to be earnings enhancing with immediate effect.
Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Group”), Europe’s largest adult stem cell storage bank, announces that it is publishing a trading update for the year ended 31 December 2007 and that it has acquired its Hungarian distributor, Sejtbank. Cryo-Save was admitted to AIM on 6 November 2007.
